Introduction {#sec1-1}
============

Breast cancer is the most frequently diagnosed cancer among women, which contributed to 25% of all cancer cases in women worldwide (Nedooshan et al., 2017; Yazdi et al., 2015). The etiology of breast cancer is still not fully understood. It is a heterogeneous disease in regard to its clinical, histological, and molecular profile (Kamali et al., 2017; Kamali et al., 2017). At present, genetic polymorphisms are increasingly recognized as contributors to breast cancer risk. Numerous breast cancer risk factors such as age, age at menarche, age at first childbirth, and number of first-degree female relatives with breast cancer have been identified (Shiryazdi et al., 2015; Shiryazdi et al., 2015). The heritable defects of BRCA1 and BRCA2 are identified in less than 50% of hereditary breast cancer cases (Forat-Yazdi et al., 2015; Forat-Yazdi et al.,2017; Neamatzadeh et al., 2015). Several epidemiological and molecular studies indicates ACE I/D gene polymorphism as a risk factor involved in the initiation and progression of different disease such as diabetic nephropathy, end-stage renal disease(ESRD) and cancer (Buraczynska et al., 2006; Singh et al., 2018).

The ACE, a zinc metalloenzyme, is a member of renin--angiotensin system (RAS) or the renin--angiotensin--aldosterone system (RAAS) involved in catalyzing the conversion of angiotensin I into a physiologically active peptide angiotensin II (Fagyas et al., 2014). The ACE gene (Gene ID: 1636; also known as: DCP; ACE1; DCP1; CD143) is localized in human chromosomes 17q23, comprises 26 exons, spans about 21 kb and more than 13 polymorphisms in this gene have been identified with susceptibility to different disease such as ACE I/D (rs 1799752), A240A\>T (rs4291), 2350G\>A (rs4344), and 17888C\>T (rs4359) (Sayed-Tabatabaei et al., 2006). The ACE insertion/deletion (I/D) polymorphism is a nonsense and 287 bp Alu repeat sequence of DNA in the intron 16 of ACE gene, which represented by "Insertion" or "I", and absence of the same denotes "Deletion" or "D" (Mahjoub et al., 2016).

To date, several studies have evaluated the association between ACE I/D polymorphism and breast cancer risk. However, the results are inconsistent and inconclusive, with some studies found significant association, while others were not. Although previous meta-analyses has tried to explore the whether the ACE I/D polymorphism is associated with increased risk of breast cancer, recently, new case-control studies in different ethnicities have been published. Therefore, we pooled all eligible studies in the present meta-analysis to evaluate the association of ACE I/D polymorphism with the risk of breast cancer.

Materials and Methods {#sec1-2}
=====================

Search Strategy {#sec2-1}
---------------

Electronic databases of PubMed (Medline), EMBASE and Google Scholar, ISI Web of Knowledge, Chinese National Knowledge Infrastructure database (CNKI), and Chinese Biomedical Literature Database (CBM) were used to identify all studies that evaluate the associations of ACE I/D polymorphism with breast cancer up to June 01, 2018. The key words used for search were: (breast, cancer, carcinoma, tumor, neoplasm, malignancy) and (angiotensin converting enzyme insertion/deletion, ACE I/D) and (polymorphism, mutation, variant, SNP). In addition, we have hand searched reference list of all eligible studies and related reviews for additional suitable studies. Studies in English, Persia, chinses and Portuguese languages were included to the meta-analysis. In addition, we have not set any restriction on time period, sample size, and ethnicity.

Data extraction {#sec2-2}
---------------

Two authors reviewed and extracted data independently in accordance with the inclusion criteria. The results were compared, and if any disagreement appeared, a third investigator was invited to evaluate such studies, and then the discrepancy was resolved by discussion. The following data were extracted: the name of first author, year of publication, country, ethnicity, sample size, allele numbers and genotype distributions in cases and controls, and the results of Hardy-Weinberg equilibrium (HWE) test.

Inclusion and exclusion criteria {#sec2-3}
--------------------------------

The studies included in this meta-analysis had to meet the following criteria: (1) only case-control or cohort studies; (2) evaluation of the ACE I/D polymorphism and breast cancer risk; (3) provided sufficient genotyping data to calculate odds ratios (ORs) and their 95% confidence intervals (CIs). On the other side, the major reasons for study exclusion were: (1) studies were not relevant to ACE I/D polymorphism or breast cancer; (2) studies did not report genotype frequencies; (3) case only studies and control group including malignant tumor patients; (4) the design were based on sibling pairs or linkage studies; (5) reviews, case reports, abstracts, posters, letter and animal studies; and (6) overlapped or duplicated publications. When, more than one of the same populations was included in several studies, the most recently published study or the largest study with extractable data was selected. If original necessary data were unavailable in the selected studies, we have sent a request to the corresponding author for additional data.

Statistical analysis {#sec2-4}
--------------------

Pooled ORs with corresponding 95% CIs were calculated to evaluate the association between ACE I/D polymorphism and breast cancer risk. We have used the Z-test to assess the significance of the pooled OR, in which P\<0.05 was considered as statistically significant. Pooled ORs was calculated under the following five genetic models: the allele model (I vs. D), the homozygote model (II vs. DD), the heterozygote model (ID vs. DD), the dominant model (II+ID vs. DD), and the recessive model (II vs. ID+DD). The Q-test was used to evaluate between-study heterogeneity, was considered significant when p-value \<0.05. Additionally, the I2 statistics was used to quantify or describe the percentage of between-study heterogeneity, which was considered as significant when I^2^\>50% (I^2^ \<25% indicating low heterogeneity; 25%-50% indicating moderate heterogeneity; and \>50% indicating high heterogeneity) (Sobhan et al., 2018; Yazdi et al., 2017). Therefore, a fixed-effects model (the Mantel--Haenszel method) as used to calculate pooled OR in the absence of heterogeneity (Mantel and Haenszel, 1959). Otherwise, the random-effects model (the DerSimonian and Laird method) was used (DerSimonian and Laird 1986). The control genotypes were tested for Hardy- Weinberg equilibrium (HWE) using the Goodness of fit Chi-square test. The heterogeneity was adjusted by subgroup analysis and meta-regression. Sensitivity analyses were conducted to evaluate the effect of individual study on pooled ORs and assess the stability of results. The evidence of potential publication bias was evaluated by the funnel plot and Egger's test, in which P\<0.01 was considered as statistically significant. In addition, publication bias was assessed using visual inspection an asymmetric plot (Begg and Mazumdar, 1994; Egger et al., 1997). When publication bias observed, the Duval and Tweedie non-parametric ''trim and fill'' method was applied to adjust for it. The Comprehensive Meta-Analysis (CMA) Version 2.2 software program (Biostat, USA) was used to perform all statistical analysis, and all the P values were two sided.

Results {#sec1-3}
=======

According to the present meta-analysis selection criteria, a total of 127 articles were retrieved by literatures search of online databases and hand searching. After review of titles and abstracts, 139 publications were excluded because were reviews, duplication and overlapping data, non-case-control studies, not relevant to ACE I/D polymorphism and breast cancer risk. Finally, a total of 20 case-control studies (Alves Corrêa et al., 2009; Felipe et al., 2011; Fishchuk and Gorovenko, 2013; Ghosh Roy et al., 2015; Gonzalez-Zuloeta Ladd et al., 2005; Haiman et al., 2003; van der Knaap et al., 2008; Koh et al., 2003; Kumar et al., 2016; Mendizábal-Ruiz et al., 2011; Namazi et al., 2010; El Sharkawy et al., 2014; Siddiqi et al., 2010; Singh et al., 2018; Xiaomei et al., 2014; Yaren et al., 2007, 2006) were included in our meta-analysis, consisting of 2,846 cases 9,299 controls. The detailed characteristics of the included studies are listed in [Table 1](#T1){ref-type="table"}. The original populations contain Singapore, Japan, Netherlands, Turkey, Brazil, Iran, India, Mexico, Colombia, Ukraine, china, and Egypt. There were 8 studies of subjects of Asians, 7 studies of subjects of Caucasian descent, 4 studies of subjects with mixed-ethnicity studies, and one study of subjects of African descent. All the genotype distributions of control subjects were in agreement with HWE for ACE I/D polymorphism except for 7 case-control studies ([Table 1](#T1){ref-type="table"}).

###### 

Characteristics of the Studies Included in the Meta-analysis

  First Author           Country       Ethnicity           Case   Control   Cases   Control   HWE                                                 
  ---------------------- ------------- ------------------- ------ --------- ------- --------- ----- ----- ----- ------ ------ ----- ------ ------ --------
  Koh 2003               Singapore     Asian               182    643       23      80        79    126   238   56     305    282   417    869    0.036
  Haiman 2003a                         African Americans   257    631       77      118       62    272   242   221    310    100   752    510    0.614
  Haiman 2003b           Japan         Asian               284    357       37      128       119   202   366   43     160    154   246    460    0.884
  Haiman 2003c                         Mixed               249    652       49      127       73    225   273   162    301    189   463    679    0.055
  Haiman 2003d                         Caucasians          292    402       84      129       79    297   287   124    187    91    435    369    0.204
  Ladd 2005              Netherlands   Caucasians          114    4203      37      55        22    129   99    1133   2192   878   4458   3948   0.002
  Yaren 2006             Turkey        Caucasians          44     46        25      17        2     67    21    28     12     6     68     24     0.028
  Yaren 2007             Turkey        Caucasians          57     52        31      24        2     85    28    33     12     7     78     26     0.005
  Van der 2008           Netherlands   Caucasians          153    655       54      67        32    175   131   185    329    141   699    470    0.815
  Alves Corrêa 2009      Brazil        Mixed               101    307       61      20        20    142   60    141    113    53    395    219    ≤0.001
  Namazi 2010            Iran          Asian               70     70        20      42        8     82    58    29     34     7     92     48     0.514
  Siddiqi 2010           India         Asian               130    228       62      43        25    167   93    96     107    25    299    157    0.552
  Mendizábal-Ruiz 2011   Mexico        Mixed               63     288       53      6         4     112   14    63     151    74    277    299    0.394
  Felipe 2011            Colombia      Mixed               50     50        10      23        17    43    57    10     24     16    44     56     0.854
  Fishchuk 2013          Ukraine       Caucasians          131    102       41      53        37    135   127   21     50     31    92     112    0.918
  Xiaomei 2014           China         Asian               123    72        61      32        30    154   92    36     19     17    91     53     ≤0.001
  El-Sharkawy 2014       Egypt         African             70     50        29      28        13    86    54    21     21     8     63     37     0.483
  Ghosh 2015             India         Asian               108    128       62      28        18    152   64    32     50     46    114    142    0.017
  Kumar 2016             India         Asian               213    213       35      86        92    156   270   24     77     112   125    301    0.061
  Singh 2018             India         Asian               155    150       86      59        10    231   79    29     74     47    132    168    0.989

HWE, Hardy Weinberg Equilibrium

Quantitative Data Synthesis {#sec2-5}
---------------------------

In the overall analysis, statistically significant association between ACE I/D polymorphism and breast cancer susceptibility was observed under the allele model (I vs. D: OR= 0.803, 95% CI 0.647-0.996, p=0.046, [Figure 1A](#F1){ref-type="fig"}), the homozygote model (II vs. DD: OR= 0.662, 95% CI 0.462-0.947, p=0.024), the heterozygote model (ID vs. DD: OR= 0.707, 95% CI 0.528-0.946, p=0.020), the dominant model (II+ID vs. DD: OR= 0.691, 95% CI 0.507-0.941, p=0.019), but not under the recessive model (II vs. ID+DD: OR= 0.841, 95% CI 0.663-1.067, p=0.154, [Figure 1B](#F1){ref-type="fig"}). When stratified, the association between ACE I/D polymorphism and breast cancer risk was observed among Asian populations under the heterozygote model (ID vs. DD: OR= 0.655, 95% CI 0.436-0.984, p=0.041) and Caucasian populations under the allele model (I vs. D: OR= 1.115, 95% CI 1.002-1.241, p=0.046), but not among mixed populations. In the subgroup analysis by studies quality (fulfilling HWE or not), a significant association between the ACE I/D polymorphism and breast cancer risk was observed under the heterozygote model (ID vs. DD: OR= 0.656, 95% CI 0.454-0.946, p=0.024).

![Forest Plots for Association between ACE I/D Polymorphism and Breast Cancer Risk. A, the allele model (I vs. D) and B, the recessive model (II vs. ID+DD).](APJCP-19-3225-g001){#F1}

Heterogeneity Test {#sec2-6}
------------------

We observed high to extreme heterogeneities under all genetic model including the allele model (I vs. D: I^2^= 88.84% and PH≤0.001), the homozygote model (II vs. DD: I^2^= 83.10% and PH≤0.001), the heterozygote model (ID vs. DD: I2= 81.79% and PH≤0.001), the dominant model (II+ID vs. DD: I^2^= 86.52% and PH≤0.001), and the recessive model (II vs. ID+DD: I^2^= 74.01% and PH≤0.001, [Table 2](#T2){ref-type="table"}). In the subgroup analysis by ethnicity, results were similar in the Asians and mixed population. While, in the Caucasians, between study heterogeneity was significantly reduced under the allele model (I vs. D: I^2^= 51.31% and PH=0.055), the heterozygote model (ID vs. DD: I^2^= 47.68% and PH=0.075), and the dominant model (II+ID vs. DD: I^2^= 46.81% and PH=0.080).

###### 

Summary Risk Estimates for Association between ACE I/D Polymorphism and Risk of Breast Cancer

  Subgroup             Genetic Model   Type of Model   Heterogeneity            Odds Ratio (OR)                 Publication Bias                   
  -------------------- --------------- --------------- --------------- -------- ----------------- ------------- ------------------ ------- ------- -------
  Overall              I vs. D         Random          88.84           ≤0.001   0.803             0.647-0.996   -1.992             0.046   0.035   0.048
  II vs. DD            Random          83.10           ≤0.001          0.662    0.462-0.947       -2.256        0.024              0.030   0.024   
  ID vs. DD            Random          81.79           ≤0.001          0.707    0.528-0.946       -2.332        0.020              0.528   0.233   
  II+ID vs. DD         Random          86.52           ≤0.001          0.691    0.507-0.941       -2.348        0.019              0.363   0.157   
  II vs. ID+DD         Random          74.01           ≤0.001          0.841    0.663-1.067       -1.427        0.154              0.234   0.048   
  By Ethnicity Asian   I vs. D         Random          90.25           ≤0.001   0.735             0.512-1.055   -1.668             0.095   0.710   0.606
  II vs. DD            Random          86.73           ≤0.001          0.578    0.303-1.103       -1.663        0.096              0.710   0.657   
  ID vs. DD            Random          74.70           ≤0.001          0.655    0.436-0.984       -2.040        0.041              0.265   0.494   
  II+ID vs. DD         Random          84.71           ≤0.001          0.628    0.388-1.015       -1.899        0.058              0.536   0.705   
  II vs. ID+DD         Random          82.10           ≤0.001          0.739    0.483-1.131       -1.394        0.163              0.265   0.513   
  Caucasian            I vs. D         Fixed           51.31           0.055    1.115             1.002-1.241   1.992              0.046   0.133   0.232
  II vs. DD            Random          62.26           0.014           0.913    0.620-1.343       -0.462        0.644              0.367   0.064   
  ID vs. DD            Fixed           47.68           0.075           0.925    0.778-1.099       -0.885        0.376              1.000   0.587   
  II+ID vs. DD         Fixed           46.81           0.080           0.964    0.821-1.132       -0.443        0.658              0.548   0.800   
  II vs. ID+DD         Random          54.24           0.041           1.044    0.772-1.414       0.282         0.778              0.035   0.018   
  Mixed                I vs. D         Random          94.34           ≤0.001   0.582             0.262-1.293   -1.329             0.184   0.308   0.299
  II vs. DD            Random          88.51           ≤0.001          0.562    0.195-1.618       -1.068        0.286              0.734   0.308   
  ID vs. DD            Random          91.16           ≤0.001          0.410    0.107-1.564       -1.306        0.192              0.734   0.330   
  II+ID vs. DD         Random          95.17           ≤0.001          0.450    0.126-1.611       -1.227        0.220              0.734   0.427   
  II vs. ID+DD         Random          68.67           0.023           0.819    0.466-1.439       -0.694        0.488              0.308   0.422   

Sensitivity Analysis {#sec2-7}
--------------------

To evaluate the robustness of the association results, a meta-analysis was performed repeatedly with each study removed. The results indicated that the fixed-effect estimates before or after the deletion of any single study were generally similar, suggesting a high stability of the meta-analysis results (data not shown). After excluding studies which not fulfilling HWE the pooled ORs were materially altered under the allele model (I vs. D: OR= 0.814, 95% CI 0.608-1.090, p=0.167), the homozygote model (ID vs. DD: OR= 0.709, 95% CI 0.439-1.147, p=0.161), and the dominant model (II+ID vs. DD: OR= 0.672, 95% CI 00.438-1.029, p=0.064; data not shown). The sensitivity analyses substantially alter the pooled ORs except heterozygote model in overall populations, suggesting that the results of this meta-analysis were generally robust.

Publication bias {#sec2-8}
----------------

Publication bias were qualitatively assessed by Begg's funnel plot and quantitatively assessed by Egger's test. A significant publication bias was detected by Egger's test under the allele model (P~Beggs~= 0.035, P~Eggers~=0.048, [Figure 2](#F2){ref-type="fig"}), the homozygote model (P~Beggs~= 0.030, P~Eggers~=0.024) and the recessive model (P~Beggs~= 0.234, P~Eggers~=0.048). In the stratified analysis by ethnicity, still obvious publication bias were found among Caucasians under the recessive model (P~Beggs~= 0.035, P~Eggers~=0.018). Thus, we have repeated meta-analysis with the ''trim and fill'' method to adjust publication bias under the three genetic models. Adjusting these three genetic models by ''trim and fill'' method did not influence the conclusion, which indicated the robustness our results (data not shown).

![Begg's Funnel Plots for the Association between ACE I/D Polymorphism and Breast Cancer under the Allele Model (I vs. D).](APJCP-19-3225-g002){#F2}

Discussion {#sec1-4}
==========

ACE is well known to be a key part of the RAS that regulates blood pressure through conversion of the angiotensin I to the angiotensin II by removing the two C-terminal amino acids. The ACE I/D polymorphism, the most widely studied polymorphism within ACE gene, which individuals carrying the D allele have higher ACE activity. Rigat et al has initially detected ACE I/D polymorphism by restriction fragment length polymorphism (RFLP) analysis (Rigat et al., 1990). There have been a few meta-analyses focusing on association of ACE I/D polymorphism with breast cancer risk. However, most of these analyses wrongly not included all published studies and a new meta-analysis is needed to give a comprehensive conclusion due to the increasing data of case-control studies.

This present meta-analysis, including 2846 breast cancer cases and 9,299 controls from 20 case-control studies, explored the association between the ACE I/D polymorphism and breast cancer risk. This is the largest scale meta-analysis so far. Our results suggested that the ACE I/D polymorphism was significantly associated with increased risk of breast cancer. To further elucidate the association between the ACE I/D and the risk of breast cancer, we have performed subgroup analysis. In subgroup analysis by ethnicity, we found a marginal association of ACE I/D and breast cancer among Asian populations under the heterozygote model (ID vs. DD: OR= 0.655, 95% CI 0.436-0.984, p=0.041) and Caucasian populations under the allele model (I vs. D: OR= 1.115, 95% CI 1.002-1.241, p=0.046), but not among mixed populations. The inconsistency of genetic effects across the ethnicities was detected for breast cancer, and it showed that Asian populations had a greater genetic risk in developing depression on account of genetic variation in this locus than White populations. Results of this meta-analysis indicated that there was a significant association of ACE I/D polymorphism with increased risk of breast cancer. The present meta-analysis results are inconsistent with all previous the meta-analysis (Li et al., 2015; Pei and Li, 2012; Xi et al., 2011; Zhang et al., 2011). The inconsistent results between ours and previous meta-analyses might mainly be due to relevant smaller sample size from previous meta-analyses. Furthermore, most studies included in the present meta-analysis performed among Asians, while previous meta-analyses only had very limited Asian populations.

The great discrepancy among different studies indicated the existence of between-studies heterogeneity and it is generally introduced that meta-analyses should assess heterogeneity (Abedinzadeh et al., 2015; Nedooshan et al., 2017). There are several factors responsible for such heterogeneity such as the study designs, ethnicity of cases and controls, genotyping method, sample size, selection criteria and etc., (Mehdinejad et al., 2017; Sobhan et al., 2017). In the present meta-analysis, there was an extreme heterogeneity (I^2^ = 75% to 100%) under all five genetic models in overall estimations. Thus, we have performed stratified analysis by ethnicity to identify possible sources for the observed heterogeneity. However, after stratified analysis, there were still heterogeneities in Asian and mixed populations.

To our best knowledge, the present meta-analysis is the most comprehensive, latest one and has the largest sample size. Thus, the statistical power of our analyses was noticeably increased as a large sample size pooled from different studies, and has more statistical powerful than any single case-control study and previous meta-analyses. However, the conclusions of this meta-analysis should be interpreted cautiously due to some limitations. First, the number of published studies was not sufficiently large for stratified analyses by ethnicity. Because of limited available data for mixed population and Africans, our results should be interpreted with caution. Therefore, larger studies are required to explore the association ACE I/D polymorphism with susceptibility to the breast cancer in different ethnicities, especially among mixed population and Africans. Second, there was a significant between study heterogeneity under all five genetic models in overall estimations. One possible reason for such heterogeneity is a wide variation in various included ethnicities. Therefore, we have performed subgroup analysis by ethnicity to eliminate heterogeneity. However, the results showed that the heterogeneity did not reduced or disappeared significantly. Third, there was a significant publication bias under three genetic models which could influence the results of our meta-analysis. However, adjusting pooled ORs for these genetic models by ''trim and fill'' method did not influence the conclusion, which indicated the robustness our results. Forth, we included only published studies, so there was space for publication bias, which in fact was confirmed by formal statistical tests. Finally, lacking the original data for the included studies limited our further evaluation of potential interactions among gene--gene, gene--environment, or even different polymorphism loci of the ACE gene.

In summary, the present meta-analysis suggested that suggest that the ACE I/D polymorphism is significantly associated with risk of breast cancer. Considering the limited sample size among different ethnicities included in the present meta-analysis, further well-designed and unbiased studies with larger sample studies are needed to confirm our results.
